Q3/2024 9/30/2024 EPS -0.860 ZacksConsensus -1.030 ActVsEst 0.170 - Beat
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: Wall Street Horizon
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor, in the Phase 1 KONQUER-101 Trial for Advanced Solid TumorsBusiness Wire
- Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CMGlobeNewswire
- BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Redburn Atlantic. They set a "buy" rating and a $50.00 price target on the stock.MarketBeat
- Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (=90%), Approved in Japan to Treat ATTR-CMGlobeNewswire
- BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at JPMorgan Chase & Co. from $44.00 to $50.00. They now have an "overweight" rating on the stock.MarketBeat
BBIO
Earnings
- 8/1/24 - Beat
BBIO
Sec Filings
- 3/27/25 - Form 4
- 3/21/25 - Form 4
- 3/21/25 - Form 4
- BBIO's page on the SEC website